Revenue: As of FY2025 Q3, the actual value is USD 2.217 M, missing the estimate of USD 2.5 M.EPS: As of FY2025 Q3, the actual value is USD 0.56.EBIT: As of FY2025 Q3, the actual value is USD -2.697 M.<h3>Segment Revenue</h3><ul><li>Net Sales: For the three months ended September 30, 2025, net sales were $2,217,000, a decrease of 6.3% compared to $2,367,000 for the same period in 2024.</li><li>Net Sales: For the nine months ended September 30, 2025, net sales were $5,846,000, a decrease of 8.9% compared to $6,418,000 for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Profit: For the three months ended September 30, 2025, gross profit was $1,445,000, a decrease from $1,656,000 in the same period in 2024.</li><li>Gross Profit: For the nine months ended September 30, 2025, gross profit was $3,470,000, a decrease from $4,321,000 in the same period in 2024.</li><li>Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $4,124,000, compared to $3,088,000 for the same period in 2024.</li><li>Operating Expenses: Total operating expenses for the nine months ended September 30, 2025, were $12,030,000, compared to $12,550,000 for the same period in 2024.</li><li>Net Income (Loss): For the three months ended September 30, 2025, net income was $468,000, compared to $2,358,000 for the same period in 2024.</li><li>Net Income (Loss): For the nine months ended September 30, 2025, net loss was -$15,099,000, compared to -$9,697,000 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was -$7,780,000, compared to -$8,087,000 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: For the nine months ended September 30, 2025, net cash used in investing activities was -$102,000, compared to -$37,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $5,888,000, compared to $6,246,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>International Revenue: International revenue represented 0% of net sales for the three months ended September 30, 2025, compared to 3% for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company announced its decision to exit selected international operations to focus on the U.S. market, where it sees the strongest growth and clinical demand. This strategic realignment supports Nuwellis’ core business strategy of investing in markets driving revenue growth.</li><li>Non-Core Business: The company announced the termination of its REVERSE-HF clinical trial to prioritize resources in areas demonstrating the greatest potential for patient impact and business growth, anticipating savings of approximately $4.0 million over the next 2.5 years.</li><li>Priority: The company believes its existing capital resources will be sufficient to support its operating plan into the first quarter of 2026, but it will seek to raise additional capital to support growth or other strategic initiatives through debt, equity, or a combination thereof.</li></ul>

Nuwellis | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 2.217 M